Skip to main content

Crystal Adam's Form 4 filing

C4 Therapeutics, Inc. (CCCC) · filed Oct 5, 2021

Accession no.
0001209191-21-059512
Filed
Oct 5, 2021
Trade date
Oct 1, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $681.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Crystal AdamCIK 0001825445Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 1, 2021Common StockMOption exerciseAcquired+15,000$4.98+$74,70015,000Direct
Oct 1, 2021Common StockSSaleDisposed−1,712$44.25F2−$75,75613,288Direct
Oct 1, 2021Common StockSSaleDisposed−8,176$45.32F3−$370,536.325,112Direct
Oct 1, 2021Common StockSSaleDisposed−5,112$45.99F4−$235,100.880Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 1, 2021Common StockMOption exerciseDisposed−15,000$0.00$0168,108Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.57 to $44.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.845. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.89 to $46.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)